Ricevi le ultime notizie sulle azioni Cardiol Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CRDL

Ultime notizie per

Cardiol Therapeutics

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Biote

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Vyome Holdings

ImageneBio

Intercure

Incannex Healthcare

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NRX Pharmaceuticals

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Hldgs

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Cassava Sciences

Scilex Holding

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Talphera

Turn Therapeutics

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Cardiol Therapeutics (CRDL) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Vendite allo scoperto

Rapporto azionario

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Comments

Cardiol Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO